Chemopreventive effect of a xanthine oxidase inhibitor, 1'-acetoxychavicol acetate, on rat oral carcinogenesis. 1996

M Ohnishi, and T Tanaka, and H Makita, and T Kawamori, and H Mori, and K Satoh, and A Hara, and A Murakami, and H Ohigashi, and K Koshimizu
First Department of Pathology, Gifu University School of Medicine, Japan.

The effect of a xanthine oxidase inhibitor, 1'-acetoxychavicol acetate (ACA), on 4-nitroquinoline 1-oxide (4-NQO)-induced oral carcinogenesis was investigated in male F344 rats. All rats except those in the ACA-alone and untreated groups were given 4-NQO (20 ppm) In the drinking water for 8 weeks to induce oral cancer. Starting 1 week before the 4-NQO exposure, animals were fed diet containing 100 ppm or 500 ppm ACA for 10 weeks, followed by the basal diet without ACA for 22 weeks. Other groups were fed the diet containing ACA at 100 ppm or 500 ppm for 22 weeks, starting 1 week after the cessation of 4-NQO exposure. The remaining groups consisted of rats given 500 ppm ACA alone or untreated rats. At the termination of the experiment (32 weeks), the incidences of tongue neoplasms and preneoplastic lesions, polyamine levels in the tongue tissue, and cell proliferation activity estimated in terms of 5-bromodeoxyuridine (BrdU)-labeling index and by morphometric analysis of silver-stained nucleolar organizer regions' protein (AgNORs) were compared among the groups. Feeding of ACA at the two doses during initiation or postinitiation significantly decreased the development of tongue carcinoma (93-100% reduction, P < 0.001) and preneoplasia (43-50% reduction for hyperplasia and 34-48% reduction for dysplasia, P < 0.05). There were no such lesions in rats fed ACA alone or those in the untreated control group. The number of AgNORs per cell nucleus was significantly decreased by feeding of ACA at a high dose (500 ppm) (29% inhibition, P < 0.05). The BrdU-labeling index was also reduced by dietary administration of ACA (23-32% inhibition, P < 0.01). In addition, ACA feeding reduced tongue polyamine levels (35-40% inhibition, P < 0.05). These results indicate that ACA inhibited rat oral carcinogenesis, and such inhibition might be related to suppression of cell proliferation in the oral mucosa by the xanthine oxidase inhibitor.

UI MeSH Term Description Entries
D008297 Male Males
D009061 Mouth Mucosa Lining of the ORAL CAVITY, including mucosa on the GUMS; the PALATE; the LIP; the CHEEK; floor of the mouth; and other structures. The mucosa is generally a nonkeratinized stratified squamous EPITHELIUM covering muscle, bone, or glands but can show varying degree of keratinization at specific locations. Buccal Mucosa,Oral Mucosa,Mucosa, Mouth,Mucosa, Oral
D009697 Nucleolus Organizer Region The chromosome region which is active in nucleolus formation and which functions in the synthesis of ribosomal RNA. Nucleolar Organizer,Nucleolar Organizers,Nucleolus Organizer Regions,Organizer Region, Nucleolus,Organizer Regions, Nucleolus,Organizer, Nucleolar,Organizers, Nucleolar,Region, Nucleolus Organizer,Regions, Nucleolus Organizer
D011230 Precancerous Conditions Pathological conditions that tend eventually to become malignant. Preneoplastic Conditions,Condition, Preneoplastic,Conditions, Preneoplastic,Preneoplastic Condition,Condition, Precancerous,Conditions, Precancerous,Precancerous Condition
D011916 Rats, Inbred F344 An inbred strain of rat that is used for general BIOMEDICAL RESEARCH purposes. Fischer Rats,Rats, Inbred CDF,Rats, Inbred Fischer 344,Rats, F344,Rats, Inbred Fisher 344,CDF Rat, Inbred,CDF Rats, Inbred,F344 Rat,F344 Rat, Inbred,F344 Rats,F344 Rats, Inbred,Inbred CDF Rat,Inbred CDF Rats,Inbred F344 Rat,Inbred F344 Rats,Rat, F344,Rat, Inbred CDF,Rat, Inbred F344,Rats, Fischer
D001973 Bromodeoxyuridine A nucleoside that substitutes for thymidine in DNA and thus acts as an antimetabolite. It causes breaks in chromosomes and has been proposed as an antiviral and antineoplastic agent. It has been given orphan drug status for use in the treatment of primary brain tumors. BUdR,BrdU,Bromouracil Deoxyriboside,Broxuridine,5-Bromo-2'-deoxyuridine,5-Bromodeoxyuridine,NSC-38297,5 Bromo 2' deoxyuridine,5 Bromodeoxyuridine,Deoxyriboside, Bromouracil
D002273 Carcinogens Substances that increase the risk of NEOPLASMS in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included. Carcinogen,Oncogen,Oncogens,Tumor Initiator,Tumor Initiators,Tumor Promoter,Tumor Promoters,Initiator, Tumor,Initiators, Tumor,Promoter, Tumor,Promoters, Tumor
D002455 Cell Division The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION. M Phase,Cell Division Phase,Cell Divisions,Division Phase, Cell,Division, Cell,Divisions, Cell,M Phases,Phase, Cell Division,Phase, M,Phases, M
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme

Related Publications

M Ohnishi, and T Tanaka, and H Makita, and T Kawamori, and H Mori, and K Satoh, and A Hara, and A Murakami, and H Ohigashi, and K Koshimizu
September 1997, Japanese journal of cancer research : Gann,
M Ohnishi, and T Tanaka, and H Makita, and T Kawamori, and H Mori, and K Satoh, and A Hara, and A Murakami, and H Ohigashi, and K Koshimizu
May 1997, Carcinogenesis,
M Ohnishi, and T Tanaka, and H Makita, and T Kawamori, and H Mori, and K Satoh, and A Hara, and A Murakami, and H Ohigashi, and K Koshimizu
August 1995, Bioscience, biotechnology, and biochemistry,
M Ohnishi, and T Tanaka, and H Makita, and T Kawamori, and H Mori, and K Satoh, and A Hara, and A Murakami, and H Ohigashi, and K Koshimizu
December 2003, Cancer letters,
M Ohnishi, and T Tanaka, and H Makita, and T Kawamori, and H Mori, and K Satoh, and A Hara, and A Murakami, and H Ohigashi, and K Koshimizu
January 1976, Recent advances in studies on cardiac structure and metabolism,
M Ohnishi, and T Tanaka, and H Makita, and T Kawamori, and H Mori, and K Satoh, and A Hara, and A Murakami, and H Ohigashi, and K Koshimizu
August 2019, Journal of clinical medicine research,
M Ohnishi, and T Tanaka, and H Makita, and T Kawamori, and H Mori, and K Satoh, and A Hara, and A Murakami, and H Ohigashi, and K Koshimizu
November 1961, Nature,
M Ohnishi, and T Tanaka, and H Makita, and T Kawamori, and H Mori, and K Satoh, and A Hara, and A Murakami, and H Ohigashi, and K Koshimizu
September 1998, Pediatric research,
M Ohnishi, and T Tanaka, and H Makita, and T Kawamori, and H Mori, and K Satoh, and A Hara, and A Murakami, and H Ohigashi, and K Koshimizu
April 1953, The Journal of biological chemistry,
M Ohnishi, and T Tanaka, and H Makita, and T Kawamori, and H Mori, and K Satoh, and A Hara, and A Murakami, and H Ohigashi, and K Koshimizu
January 1962, Nature,
Copied contents to your clipboard!